Logo.png
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
06 janv. 2022 06h00 HE | BioRestorative Therapies, Inc
MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies,...
Logo.png
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
21 déc. 2021 06h00 HE | BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
Logo.png
BioRestorative Therapies Announces Closing of $23 Million Public Offering
09 nov. 2021 14h20 HE | BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
Be Humance Launches New Collection of Self-Care Essentials to Help De-Stress and Relax
28 oct. 2021 11h00 HE | Be Humance
LOS ANGELES, Oct. 28, 2021 (GLOBE NEWSWIRE) -- According to a recent survey conducted by the American Psychological Association (AMA), more than 80% of Americans report emotions associated with...
New.jpg
BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
26 oct. 2021 16h05 HE | BioRestorative Therapies, Inc
MELVILLE, NY, Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BRTX” or the “Company”) (OTC: BRTX), a life sciences company focused on adult stem cell-based therapies, today...
ritter.jpg
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
16 avr. 2020 14h07 HE | Ritter Pharmaceuticals, Inc.
Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
ritter.jpg
Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019
31 mars 2020 17h27 HE | Ritter Pharmaceuticals, Inc.
Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
ritter.jpg
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
21 janv. 2020 09h15 HE | Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
ritter.jpg
Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update
20 juin 2019 09h15 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
ritter.jpg
Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update
29 mars 2019 09h00 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...